

**DESCRIPTION**


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human TACI/TNFRSF13B in direct ELISAs. In direct ELISAs, no cross-reactivity with recombinant human BCMA or recombinant mouse TACI is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>1</sub> Clone # 165604
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human TACI/TNFRSF13B Ser2-Thr166 Accession # O14836
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

**APPLICATIONS**

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Flow Cytometry</b>	0.25 µg/10 <sup>6</sup> cells	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	
<b>Blockade of Receptor-ligand Interaction</b>	In a functional ELISA, 0.05-0.2 µg/mL of this antibody will block 50% of the binding of 50 ng/mL of Recombinant Human BAFF/BLYS/TNFSF13B (Catalog # 2149-BF) to immobilized Recombinant Human TACI/TNFRSF13B Fc Chimera (Catalog # 174-TC) coated at 1 µg/mL (100 µL/well). At 10 µg/mL, this antibody will block >90% of the binding.	

**DATA**



**PREPARATION AND STORAGE**

<b>Reconstitution</b>	Reconstitute at 0.5 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

TACI, transmembrane activator and CAML-interactor, is a member of the TNF receptor superfamily. TACI is a type III membrane protein with an extracellular N-terminus in the absence of a cleaved signal sequence. The extracellular region of TACI contains two cysteine rich domains. Within the TNFRSF, it shares the highest homology with BCMA. TACI and BCMA have both been shown to bind APRIL and BAFF, members of the TNF ligand superfamily. TACI is expressed on the cell surface of B cells and activated, but not resting, T cells. Analogous to BCMA, data suggests that TACI may play an important role in B cell development, function and regulation. Human TACI is a 293 amino acid (aa) protein consisting of a 166 aa extracellular domain, a 20 aa transmembrane domain, and a 107 aa intracellular domain. Human and mouse TACI share 54% amino acid identity.

## References:

1. Xia, X.-Z. *et al.* (2000) *J. Exp. Med.* **192**:137.
2. von Bulow, G.U. *et al.* (1997) *Science*, **278**:138.
3. Gross, J.A. *et al.* (2000) *Nature* **404**:995.
4. Marsters, S.A. *et al.* (2000) *Curr. Biol.* **10**:785.
5. Yan, M. *et al.* (2000) *Nature Immunol.* **1**:37.
6. Wu, Y. *et al.* (2000) *J. Biol. Chem.* **275**:35478.